The impact of body composition on liver and kidney function and blood lipids in patients with polycystic ovary syndrome

doi:10.3969/j.issn.1006-7795.2024.04.010

Abstract

Abstract: Objective To analyze the impact of body composition on liver and kidney function and blood lipids in women with polycystic ovary syndrome (PCOS).Methods This cross-sectional case-control study recruited 678 women aged 20-40 years from the Department of Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, between October 2020 and December 2023. According to the 2004 international Rotterdam criteria, participants were divided into a PCOS group (n=578) and a control group (n=100). Height, weight, waist circumference, and hip circumference were measured, and body mass index (BMI) was calculated. Body fat percentage (BFP) was measured. Alanine transaminase (ALT), aspartate aminotransferase (AST), creatinine (Cre), uric acid (UA), blood urea nitrogen (BUN), total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and lipoprotein(a) ［LP(a)］ levels were detected. The impact of body composition on liver function in PCOS was analyzed.Results PCOS group had significantly higher body weight, waist circumference, and BMI than the control group (all P<0.05). ALT, AST, and UA levels in the PCOS group were significantly higher than those in the control group (all P<0.05). There were no statistically significant differences in BUN, Cre, and HDL-C between the PCOS and control groups. The body fat percentage in the PCOS group was significantly higher than that in the control group (P<0.05), with 64.07% of PCOS patients being overweight or obese. The abnormal transaminase rate in the PCOS group was 12.8%, while that in overweight and obese PCOS patients was 17.86%. The abnormal transaminase rate in overweight and obese PCOS patients was significantly higher than that in lean PCOS patients and the control group (both P<0.05). Regarding blood lipids, PCOS patients had significantly higher TC, TG, LDL-C, and LP(a) levels than the control group.Conclusions Patients with PCOS, especially those who are overweight or obese, face higher risk of liver dysfunction and dyslipidemia. Therefore, the management of PCOS patients should pay special attention to the impact of body composition on liver and kidney function as well as lipid levels. The overall health and long-term quality of life of PCOS patients can be improved, through controlling weight, improving insulin resistance, regulating diet, and increasing physical activity.

Key words: polycystic ovary syndrome, body composition, liver function, kidney function, blood lipid levels

CLC Number:

R711

Jiang Lingling, Ruan Xiangyan, Li Yanqiu, Zhang Mingzhen, Wang Zecheng, Yang Yu , Liu Lili, Alfred O. Mueck. The impact of body composition on liver and kidney function and blood lipids in patients with polycystic ovary syndrome[J]. Journal of Capital Medical University, 2024, 45(4): 623-628.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2024.04.010

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2024/V45/I4/623

References

［1］ Azziz R, Carmina E, Chen Z J, et al. Polycystic ovary syndrome［J］. Nat Rev Dis Primers, 2016, 2: 16057.
［2］ Yang R, Li Q, Zhou Z H, et al. Changes in the prevalence of polycystic ovary syndrome in China over the past decade［J］. Lancet Reg Health West Pac, 2022, 25: 100494.
［3］ Walker K, Decherney A H, Saunders R. Menstrual dysfunction in PCOS［J］. Clin Obstet Gynecol, 2021, 64(1): 119-125.
［4］ Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey［J］. Int J Adolesc Med Health, 2021, 33(6): 367-373.
［5］ Zhang J H, Hu J, Zhang C X, et al. Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease［J］. Exp Ther Med, 2018, 15(5): 4259-4264.
［6］ Li A A, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease［J］. Gut Liver, 2020, 14(2): 168-178.
［7］ Holmer M, Melum E, Isoniemi H, et al. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries［J］. Liver Int, 2018, 38(11): 2082-2090.
［8］ Zhang J, Xu J H, Qu Q Q, et al. Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: a Meta-analysis of cohort studies［J］. Front Cardiovasc Med, 2020, 7: 552421.
［9］ Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome［J］. Fertil Steril, 2004, 81(1): 19-25.
［10］中国医疗保健国际交流促进会营养与代谢管理分会,中国营养学会临床营养分会,中华医学会糖尿病学分会,等. 中国超重/肥胖医学营养治疗指南(2021)［J］. 中国医学前沿杂志: 电子版, 2021, 13(11): 1-55.
［11］ Chang S, Dunaif A. Diagnosis of polycystic ovary syndrome: which criteria to use and when?［J］. Endocrinol Metab Clin North Am, 2021, 50(1): 11-23.
［12］ Khan K A, Stas S, Kurukulasuriya L R. Polycystic ovarian syndrome［J］. J Cardiometab Syndr, 2006, 1(2): 125-130; quiz 131-132.
［13］ Wang D X, Nan N, Bing H, et al. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome［J］. Front Endocrinol, 2023, 14: 1241734.
［14］ Vrbikova J, Fanta M, Cibula D, et al. Impaired glucose metabolism in women with polycystic ovary syndrome［J］. Gynecol Obstet Invest, 2009, 68(3): 186-190.
［15］ Yu J, Zhou Y L, Ding J, et al. Characteristics and possible mechanisms of metabolic disorder in overweight women with polycystic ovary syndrome［J］. Front Endocrinol, 2022, 13: 970733.
［16］ Stener-Victorin E, Baghaei F, Holm G, et al. Effects of acupuncture and exercise on insulin sensitivity, adipose tissue characteristics, and markers of coagulation and fibrinolysis in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial［J］. Fertil Steril, 2012, 97(2): 501-508.
［17］ Yousuf S D, Ganie M A, Jeelani S, et al. Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor Ⅷ among women with polycystic ovary syndrome: an observational pilot study［J］. Indian J Med Res, 2018, 148(Suppl): S151-S155.
［18］ Kelley C E, Brown A J, Diehl A M, et al. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome［J］. World J Gastroenterol, 2014, 20(39): 14172-14184.
［19］ Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?［J］. Endocrine, 2016, 51(2): 211-221.
［20］ Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, et al. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic fatty liver disease; a meta-analysis［J］. Hepat Mon, 2014, 14(11): e23235.
［21］ Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases［J］. Hepatology, 2018, 67(1): 328-357.
［22］ Frias-Toral E, Garcia-Velasquez E, De Los A C M, et al. Polycystic ovary syndrome and obesity: clinical aspects and nutritional management［J］. Minerva Endocrinol, 2022, 47(2): 215-241.
［23］ Bizoń A, Franik G, Niepsuj J, et al. The associations between sex hormones and lipid profiles in serum of women with different phenotypes of polycystic ovary syndrome［J］. J Clin Med, 2021, 10(17): 3941.
［24］ Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome［J］. Dig Liver Dis, 2015, 47(3): 181-190.
［25］ Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?［J］. J Hepatol, 2018, 68(2): 335-352.

[1]	Zhao Yue, Ruan Xiangyan, Wang Yuejiao, Ma Jun, Jin Jing. Diagnostic value of multiple androgen indexes measured by LC-MS/MS for polycystic ovary syndrome [J]. Journal of Capital Medical University, 2024, 45(4): 602-608.
[2]	Zhang Mingzhen, Ruan Xiangyan, Min Min, Alfred O. Mueck. Effect of Orlistat comprehensive intervention on lipoprotein(a) and glycolipid metabolism and hepatorenal function in overweight or obese patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2023, 44(4): 544-549.
[3]	Tian Xuanxuan, Ruan Xiangyan, Jin Jing, Wang Juan, Cheng Jiaojiao. Investigation on awareness of the benefits from lifestyle intervention in patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2023, 44(4): 555-560.